Work

PINP levels in patients with newly diagnosed heart failure are associated with myocardial fibrosis and clinical outcomes

Year: 2026

Type: article

Abstract: OBJECTIVES: To investigate the association of Procollagen I N-Terminal Propeptide (PINP) with myocardial fibrosis (MF) and its predictive effect on major adverse cardiovascular events (MACEs) in patients with primary diagnosis of heart failure (HF). METHODS: A total of 76 newly diagnosed HF patients with reduced ejection fraction were followed up for one year. Serum PINP levels and extracellular volumes (ECV) quantified by cardiac magnetic resonance(CMR) imaging at baseline were collected. MF was defined when a ECV value was greater than 28.5%. The first MACEs defined as rehospitalization and/or cardiovascular death, were recorded during the visit. RESULTS: The levels of PINP in patients with MF were higher than those in patients without MF (39.90 VS 49.10 ng/ml, P = 0.030). Multivariate logistic regression analysis showed that PINP was an independent risk factor for MF (OR 1.058, 95% CI 1.018 ~ 1.098, P = 0.004). The linear regression model showed a linear correlation between the PINP levels and ECVs (R = 0.280, P = 0.014). Patients with higher PINP levels had a significant increased risk of incident MACE than those with lower PINP levels (HR 1.95, 95%CI 1.03 ~ 3.69, P = 0.033). CONCLUSION: In patients with newly diagnosed HF, serum PINP levels were associated with MF and an increased risk of MACEs during a one-year follow-up.

Source: BMC Cardiovascular Disorders

DOI: 10.1186/s12872-025-05344-w